Burning Rock Biotech Limited (NASDAQ:BNR - Get Free Report) was the recipient of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 60,500 shares, a drop of 6.6% from the December 31st total of 64,800 shares. Currently, 0.7% of the shares of the company are sold short. Based on an average trading volume of 26,300 shares, the short-interest ratio is currently 2.3 days.
Burning Rock Biotech Stock Performance
Shares of BNR traded up $0.16 during mid-day trading on Friday, reaching $6.48. 8,992 shares of the company's stock traded hands, compared to its average volume of 6,712. Burning Rock Biotech has a 12 month low of $2.62 and a 12 month high of $8.99. The stock has a market capitalization of $66.38 million, a P/E ratio of -2.16 and a beta of 0.55. The business's 50-day moving average price is $6.76 and its 200-day moving average price is $5.33.
Burning Rock Biotech (NASDAQ:BNR - Get Free Report) last announced its earnings results on Tuesday, December 3rd. The company reported ($0.50) EPS for the quarter. Burning Rock Biotech had a negative return on equity of 60.68% and a negative net margin of 83.50%.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Burning Rock Biotech stock. Crcm LP bought a new position in shares of Burning Rock Biotech Limited (NASDAQ:BNR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 325,969 shares of the company's stock, valued at approximately $2,200,000. Burning Rock Biotech comprises 0.9% of Crcm LP's holdings, making the stock its 5th biggest position. Crcm LP owned about 3.18% of Burning Rock Biotech at the end of the most recent quarter. Hedge funds and other institutional investors own 30.03% of the company's stock.
About Burning Rock Biotech
(
Get Free Report)
Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
Further Reading
Before you consider Burning Rock Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Burning Rock Biotech wasn't on the list.
While Burning Rock Biotech currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
